Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma

被引:3
|
作者
Fernandez-miranda, Ismael [1 ]
Pedrosa, Lucia [1 ]
Gonzalez-Rincon, Julia [1 ,2 ]
Espinet, Blanca [3 ,4 ]
Vicente, Fatima de la Cruz [5 ]
Climent, Fina [6 ]
Gomez, Sagrario [1 ]
Royuela, Ana [7 ]
Camacho, Francisca I. [8 ]
Martin-Acosta, Paloma [9 ]
Yanguas-Casas, Natalia [1 ,10 ]
Dominguez, Marina [1 ]
Mendez, Miriam [1 ,11 ]
Colomo, Luis [3 ]
Salar, Antonio [11 ,12 ]
Horcajo, Beatriz [1 ]
Navarro, Marta [1 ]
Garcia-Cosio, Monica [12 ,13 ]
Piris-Villaespesa, Miguel [13 ,14 ]
Llanos, Marta [14 ,15 ]
Garcia, Juan F. [16 ]
Sequero, Silvia [16 ,17 ]
Mercadal, Santiago [17 ,18 ]
Garcia-Hernandez, Sonia [19 ]
Navarro, Belen [20 ]
Mollejo, Manuela [21 ]
Provencio, Mariano [1 ,22 ]
Sanchez-Beato, Margarita [1 ]
机构
[1] Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Lymphoma Res Grp, IDIPHISA, Majadahonda, Madrid, Spain
[2] Fujitsu Technol Solut SA, CoE Data Intelligence, Camino Cerro Gamos 1,Pozuelo Alarcon, Madrid, Spain
[3] Inst Hosp Mar Investigac Med IMIM, Canc Res Program, Translat Res Hematol Neoplasms Grp, Barcelona, Spain
[4] Hosp del Mar, Dept Pathol, Barcelona, Spain
[5] Univ Seville, Univ Hosp Virgen Rocio, Dept Hematol, Inst Biomed Sevilla IBIS CSIC CIBERONC, Seville, Spain
[6] Hosp Univ Bellvitge, Dept Pathol, IDIBELL, Barcelona, Spain
[7] Hosp Univ Puerta Hierro Majadahonda, Biostat Unit, IDIPHISA, CIBERESP, Madrid, Spain
[8] Hosp Univ Getafe, Dept Pathol, Madrid, Spain
[9] Hosp Univ Puerta Hierro Majadahonda, Dept Pathol, Canc Mol Pathol Grp, IDIPHISA, Majadahonda, Madrid, Spain
[10] Ctr Invest Biomed Red Fragil & Envejecimiento Salu, Madrid, Spain
[11] Hosp Univ Puerta HierroMajadahonda, Dept Med Oncol, IDIPHISA, Madrid, Spain
[12] Hosp del Mar, Dept Hematol, Barcelona, Spain
[13] Hosp Univ Ramon y Cajal, Dept Pathol, Madrid, Spain
[14] Hosp Univ Ramon y Cajal, Dept Hematol, Madrid, Spain
[15] Hosp Univ Canarias, Dept Oncol, Tenerife, Spain
[16] Hosp MD Anderson Canc Ctr, Dept Pathol, Madrid, Spain
[17] Hosp Univ San Cecilio, Dept Oncol, Granada, Spain
[18] Hosp Duran i Reynals, Dept Hematol, ICO, Barcelona, Spain
[19] Hosp Univ Canarias, Dept Pathol, Tenerife, Spain
[20] Hosp Univ Puerta Hierro, Dept Hematol, Majadahonda, Madrid, Spain
[21] Complejo Hosp Toledo, Dept Pathol, Toledo, Spain
[22] Univ Autonoma Madrid, Hosp Univ Puerta Hierro Majadahonda, Fac Med, Dept Med Oncol, Majadahonda, Madrid, Spain
关键词
follicular lymphoma; genomics; histologic transformation; predictive model; PROGNOSTIC INDEX FLIPI; 1ST-LINE IMMUNOCHEMOTHERAPY; TNFRSF14; MUTATIONS; EARLY PROGRESSION; SURVIVAL; GENETICS; OUTCOMES; RITUXIMAB; ERA;
D O I
10.1016/j.modpat.2024.100516
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Follicular lymphoma (FL) is the most frequent indolent lymphoma. Some patients (10%-15%) experience histologic transformation (HT) to a more aggressive lymphoma, usually diffuse large Bcell lymphoma (DLBCL). This study aimed to validate and improve a genetic risk model to predict HT at diagnosis.We collected mutational data from diagnosis biopsies of 64 FL patients. We combined them with the data from a previously published cohort (total n 1/4 104; 62 from nontransformed and 42 from patients who did transform to DLBCL). This combined cohort was used to develop a nomogram to estimate the risk of HT. Prognostic mutated genes and clinical variables were assessed using Cox regression analysis to generate a risk model. The model was internally validated by bootstrapping and externally validated in an independent cohort. Its performance was evaluated using a concordance index and a calibration curve. The clinicogenetic nomogram included the mutational status of 3 genes (HIST1HE1, KMT2D, and TNFSR14) and high-risk Follicular Lymphoma International Prognostic Index and predicted HT with a concordance index of 0.746. Patients were classified as being at low or high risk of transformation. The probability HT function at 24 months was 0.90 in the low-risk group vs 0.51 in the high-risk group and, at 60 months, 0.71 vs 0.15, respectively. In the external validation cohort, the probability HT function in the low-risk group was 0.86 vs 0.54 in the high-risk group at 24 months, and 0.71 vs 0.32 at 60 months. The concordance index in the external cohort was 0.552. In conclusion, we propose a clinicogenetic risk model to predict FL HT to DLBLC, combining genetic alterations in HIST1H1E, KMT2D, and TNFRSF14 genes and clinical features (Follicular Lymphoma International Prognostic Index) at diagnosis. This model could improve the management of FL patients and allow treatment strategies that would prevent or delay transformation. (c) 2024 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Rituximab Maintenance Benefits Less for Follicular Lymphoma Patients with Low Risk of the Follicular Lymphoma International Index
    Wang, Tingyu
    Li, Ru
    Lv, Rui
    Yu, Ying
    Chen, Jiawen
    Xiong, Wenjie
    Wang, Qi
    Liu, Wei
    Huang, Wenyang
    Sui, Weiwei
    An, Gang
    Xu, Yan
    Zou, Dehui
    Wang, Jianxiang
    Qiu, Lugui
    Yi, Shuhua
    Wang, Yi
    BLOOD, 2021, 138
  • [42] Analysis of the transformation of follicular lymphoma in a national registry of over a thousand patients
    Lopez-Gonzalez, A.
    Cruz, M. A.
    Sabin, P.
    Quero, C.
    Rueda, A.
    Guma, J.
    De la Cruz, L.
    Garcia Arroyo, J. R.
    Martinez-Benaclocha, N.
    Provencio, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S842 - S842
  • [43] Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients
    Geyer, Julia Turbiner
    Subramaniyam, Shivakumar
    Jiang, Yanwen
    Elemento, Olivier
    Ferry, Judith A.
    de Leval, Laurence
    Nakashima, Megan O.
    Liu, Yen-Chun
    Martin, Peter
    Mathew, Susan
    Orazi, Attilio
    Tam, Wayne
    HUMAN PATHOLOGY, 2015, 46 (02) : 260 - 271
  • [44] Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era
    Cerhan, James R.
    Nowakowski, Grzegorz S.
    Maurer, Matthew J.
    Charbonneau, Bridget
    Ghesquieres, Herve
    Novak, Anne J.
    Asmann, Yan W.
    Dogan, Ahmet
    Markcoic, Svetomir N.
    Thompson, Carrie A.
    Ansell, Stephen M.
    Weiner, George J.
    Link, Brian K.
    Habermann, Thomas M.
    Slager, Susan L.
    BLOOD, 2012, 120 (21)
  • [45] EXTERNAL VALIDATION OF A PREDICTIVE MODEL FOR ACUTE PANCREATITIS RISK IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA
    Morkos, Michael
    Amblee, Ambika
    Lienriquez, Andres
    Basu, Sanjib
    Fogelfeld, Leon
    ENDOCRINE PRACTICE, 2019, 25 (08) : 817 - 823
  • [46] VALIDATION OF THE FLIPI-L PROGNOSTIC INDEX IN PATIENTS WITH FOLLICULAR LYMPHOMA
    Pablo, Mozas
    Andrea, Rivero
    Alfredo, Rivas-Delgado
    Juan-Gonzalo, Correa
    Maria, Condom
    Ferran, Nadeu
    Eva, Gine
    Julio, Delgado
    Neus, Villamor
    Elias, Campo
    Laura, Magnano
    Armando, Lopez-Guillermo
    HAEMATOLOGICA, 2021, 106 (10) : 45 - 45
  • [47] Combined Clinical and Gene Expression Score Identifies Follicular Lymphoma Patients with High Risk of Transformation in the Rituximab Era
    Steen, Chloe Beate
    Leich, Ellen
    Myklebust, June Helen
    Lockmer, Sandra
    Wise, Jillian Frances
    Wahlin, Bjorn Engelbrekt
    Ostenstad, Bjorn
    Liestol, Knut
    Kimby, Eva
    Rosenwald, Andreas
    Smeland, Erlend Bremertun
    Holte, Harald
    Lingjaerde, Ole Christian
    Brodtkorb, Marianne
    BLOOD, 2017, 130
  • [48] The architecural pattern of FOXP3+T cells predicts risk of transformation in patients with follicular lymphoma (FL)
    Farinha, Pedro
    Ai-Tourah, Abdul
    Connors, Joseph M.
    Gascoyne, Randy D.
    BLOOD, 2007, 110 (11) : 112A - 112A
  • [49] Vascularization predicts overall survival (OS) & risk of transformation (RT) in uniformly treated patients with follicular lymphoma (FL)
    Farinha, Pedro
    Gascoyne, Randy D.
    Kyle, Alistair
    Minchinton, Andrew
    Connors, Joseph M.
    Karsan, Aly
    BLOOD, 2007, 110 (11) : 62A - 62A
  • [50] Rituximab Fails to Reduce Histologic Transformation (HT) Rate of Follicular Lymphoma (FL) to Diffuse Large B-Cell Lymphoma (DLBCL)
    Marciscano, Ariel E.
    Gupta, Neel
    Zhang, Zhigang
    Teruya-Feldstein, Julie
    Noy, Ariela
    BLOOD, 2008, 112 (11) : 310 - 310